BiotechTube
Throne Biotechnologies

Throne Biotechnologies

San Diego, United States· Est.
thronebio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Throne Biotechnologies is pioneering a unique 'immune reset' therapy using its patented cord blood-derived stem cells (CB-SCs). The company's lead program, Stem Cell Educator Therapy, has demonstrated safety and efficacy in over 200 patients across international clinical trials and has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for type 1 diabetes. Founded in 2021 and based in San Diego, Throne is a private company leveraging a decade of clinical data to advance multiple Phase 2 trials towards commercialization in large autoimmune disease markets.

Type 1 DiabetesAlopecia AreataAutoimmune Diseases

Technology Platform

Proprietary Cord Blood-Derived Stem Cells (CB-SCs) with immune-educating capabilities, used in a closed-loop, dialysis-like Stem Cell Educator device to re-set a patient's immune system ex vivo without genetic matching.

Opportunities

The one-time, 'practical cure' approach addresses massive, lifelong markets like type 1 diabetes and alopecia areata with high unmet need.
The RMAT designation for T1D provides a potential accelerated pathway to approval and commercialization.
The platform's applicability across multiple autoimmune diseases offers significant pipeline expansion potential.

Risk Factors

The company faces significant clinical risk as it must validate earlier international trial results in controlled FDA Phase 2 studies.
As a pre-revenue private company, it carries financing risk and dependence on future capital raises.
Scaling manufacturing for a cell-based therapy presents complex logistical and cost challenges.

Competitive Landscape

Throne competes in the crowded autoimmune disease space against large pharma biologics and newer cell therapies. Its key differentiation is the one-time, immune-resetting mechanism using non-genetically matched cells, contrasting with chronic immunosuppressants, autologous cell therapies, or islet cell transplantation which requires lifelong immunosuppression.

More companies in Cell & Gene Therapy →More companies in United States →